Vlado Perkovic's Publications

Copland E, Canoy D, Nazarzadeh M et alii
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

Journal articles
2021
The Lancet Oncology
Oshima M, Jardine MJ, Agarwal R et alii
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Journal articles
2021
Kidney International
Yu J, Arnott C, Neuen BL et alii
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

Journal articles
2021
ESC Heart Failure
Feng KY, Gogate J, Damaraju CV et alii
Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

Conference Papers
2021
in METABOLISM-CLINICAL AND EXPERIMENTAL
Evans RDR, Smyth B, Levin A et alii
The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

Journal articles
2021
Kidney International
Sarraju A, Li JW, Cannon CP et alii
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Journal articles
2021
American Heart Journal
O'Hara DV, Parkhill TR, Badve SV et alii
The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

Journal articles
2021
Diabetes
Htay H, Bello AK, Levin A et alii
Hemodialysis Use and Practice Patterns: An International Survey Study

Journal articles
2021
American Journal of Kidney Diseases
Oshima M, Hara A, Toyama T et alii
Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

Journal articles
2021
Kidney International Reports
Koomen JV, Stevens J, Bakris G et alii
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

Journal articles
2021
Diabetes
Yu J, Zhou Z, Mahaffey KW et alii
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

Journal articles
2021
International Journal of Cardiology
Neuen BL, Arnott C, Perkovic V et alii
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

Journal articles
2021
Diabetes
Nataatmadja M, Krishnasamy R, Zuo L et alii
Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis

Journal articles
2021
Kidney International Reports
Wang KM, Li JW, Bhalla V et alii
Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

Journal articles
2021
Endocrinology
Jun M, Harris K, Heerspink HJL et alii
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

Journal articles
2021
Diabetes
Jardine M, Zhou Z, Lambers Heerspink HJ et alii
Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis

Journal articles
2021
Clinical Journal of the American Society of Nephrology
Kotwal S, Perkovic V
Forever starts now: Effects of glucose-lowering therapies on acute kidney injury

Journal articles
2021
Clinical Journal of the American Society of Nephrology
Perkovic V, Koitka-Weber A, Cooper ME et alii
Choice of endpoint in kidney outcome trials: Considerations from the EMPA-REG OUTCOMEVR trial

Journal articles
2021
Nephrology Dialysis Transplantation
Tuttle KR, Brosius FC, Cavender MA et alii
Sglt2 inhibition for ckd and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation

Conference Papers
2021
in Diabetes
Neuen BL, Ohkuma T, Neal B et alii
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

Journal articles
2021
American Journal of Kidney Diseases
Li C, Zhou Z, Neuen BL et alii
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

Journal articles
2021
Diabetes
Neuen BL, Jardine MJ, Perkovic V
Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?

Journal articles
2021
Nephrology Dialysis Transplantation
Muanda FT, Weir MA, Bathini L et alii
Higher-dose sitagliptin and the risk of congestive heart failure in older adults with CKD

Journal articles
2020
Clinical Journal of the American Society of Nephrology
Bakris G, Oshima M, Mahaffey KW et alii
Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial

Journal articles
2020
Clinical Journal of the American Society of Nephrology
Oshima M, Neuen BL, Li JW et alii
Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial

Journal articles
2020
Journal of the American Society of Nephrology
Mahaffey KW, Bakris G, Blais J et alii
Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE

Conference Papers
2020
in EUROPEAN HEART JOURNAL

Vlado Perkovic's Publications

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

Hemodialysis Use and Practice Patterns: An International Survey Study

Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis

Forever starts now: Effects of glucose-lowering therapies on acute kidney injury

Choice of endpoint in kidney outcome trials: Considerations from the EMPA-REG OUTCOMEVR trial

Sglt2 inhibition for ckd and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?

Higher-dose sitagliptin and the risk of congestive heart failure in older adults with CKD

Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial

Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial

Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country